The estimated Net Worth of Naseem Zojwalla is at least $1.32 Milión dollars as of 24 May 2024. Dr Zojwalla owns over 9,460 units of Olema Pharmaceuticals stock worth over $1,108,428 and over the last 3 years he sold OLMA stock worth over $209,315.
Dr has made over 6 trades of the Olema Pharmaceuticals stock since 2023, according to the Form 4 filled with the SEC. Most recently he exercised 9,460 units of OLMA stock worth $46,070 on 24 May 2024.
The largest trade he's ever made was exercising 20,000 units of Olema Pharmaceuticals stock on 25 January 2024 worth over $140,400. On average, Dr trades about 8,191 units every 21 days since 2022. As of 24 May 2024 he still owns at least 89,824 units of Olema Pharmaceuticals stock.
You can see the complete history of Dr Zojwalla stock trades at the bottom of the page.
Dr. Naseem Zojwalla M.D. is the Chief Medical Officer at Olema Pharmaceuticals.
Dr D is 48, he's been the Chief Medical Officer of Olema Pharmaceuticals since . There are 6 older and 2 younger executives at Olema Pharmaceuticals. The oldest executive at Olema Pharmaceuticals, Inc. is Dr. Peter J. Kushner Ph.D., 82, who is the Chief Scientific Officer.
Naseem's mailing address filed with the SEC is C/O OLEMA PHARMACEUTICALS, INC., 780 BRANNAN ST, SAN FRANCISCO, CA, 94103.
Over the last 4 years, insiders at Olema Pharmaceuticals have traded over $60,548,717 worth of Olema Pharmaceuticals stock and bought 5,935,941 units worth $82,289,865 . The most active insiders traders include Partners L P/Ilbiotechnolog..., G. Walmsley Graham a Biocapital Advisors Lp Para.... On average, Olema Pharmaceuticals executives and independent directors trade stock every 21 days with the average trade being worth of $1,893,968. The most recent stock trade was executed by Biocapital Advisors Lp Para... on 1 August 2024, trading 2,400,000 units of OLMA stock currently worth $35,808,000.
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Olema Pharmaceuticals executives and other stock owners filed with the SEC include: